News

/
/
The Joint Assessment on “Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma” available

The Joint Assessment on “Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma” available

WP5-SA4 – Updated report including the complete dataset on indirect comparisons published on EUnetHTA homepage.

Find the Joint Assessment here.

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.